A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models

June 22, 2020

American Association for Cancer Research (AACR) Virtual Annual Meeting II

6.22.19
Area of Focus
Oncology
Programs
STAT3 (KT-333)
Indications
Liquid Tumors Solid Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link